Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New roles for systemic retinoids.

Mark Lebwohl1, Martin Kathryn

  • 1Department of Dermatology, Mount Sinai School of Medicine, New York, NY, USA. lebwohl@aol.com

Journal of Drugs in Dermatology : JDD
|May 18, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Remibrutinib impact on disease control, sleep, and quality of life: Analysis of phase 3 REMIX-1/2.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026
Same author

Guselkumab Safety in Patients With Latent Tuberculosis: Analysis of 11 Studies in Psoriatic Disease.

The Journal of dermatology·2026
Same author

Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial.

JAMA dermatology·2026
Same author

Summary of Research: Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results from the SPROUT Phase 3 Trial.

Dermatology and therapy·2026
Same author

The Misdiagnosis of Pemphigus Foliaceus as Psoriasis.

International journal of dermatology·2026
Same author

Efficacy and Safety of Cosibelimab for Advanced Cutaneous Squamous Cell Carcinoma: An Expert Consensus Panel.

Journal of drugs in dermatology : JDD·2026
Same journal

A Novel Retinoid and Salicylic Acid Topical Treatment for Moderate-Severe Acne.

Journal of drugs in dermatology : JDD·2026
Same journal

INDIVIDUAL ARTICLE: Efficacy of a Dual-Serum Cosmetic System in Women With Female Pattern Hair Loss.

Journal of drugs in dermatology : JDD·2026
Same journal

A Randomized Controlled Trial Analyzing the Likeability, Usability, and In-Use Efficacy of Mineral Sunscreens Across Diverse Skin Tones.

Journal of drugs in dermatology : JDD·2026
Same journal

Safety and Effectiveness of Two Reconstitution Volumes of Poly-L-Lactic Acid for Correction of Décolletage Wrinkles.

Journal of drugs in dermatology : JDD·2026
Same journal

Randomized Controlled Study of Bacteriophages in Acne Reveals Efficacy and Novel Mechanism for Promoting Long-Term Skin Health.

Journal of drugs in dermatology : JDD·2026
Same journal

Efficacy and Safety of Clascoterone Cream 1% and Adapalene Gel 0.3% in Patients With Acne.

Journal of drugs in dermatology : JDD·2026
See all related articles

Acitretin, an oral retinoid for psoriasis, shows promise in combination therapies and as a chemopreventative agent. Further trials are needed to confirm its efficacy and safety with biologic agents.

Area of Science:

  • Dermatology and Pharmaceutical Sciences
  • Retinoid Therapy and Psoriasis Management

Background:

  • Acitretin is the sole oral retinoid approved for psoriasis treatment.
  • It demonstrates efficacy in combination, rotational, and sequential therapeutic approaches.

Purpose of the Study:

  • To review the therapeutic applications of acitretin in psoriasis.
  • To explore its potential in combination with phototherapy and biologic agents.
  • To assess its role as a chemopreventative agent.

Main Methods:

  • Review of existing literature on acitretin's use in psoriasis.
  • Analysis of studies involving combination, rotational, and sequential therapies.
  • Examination of chemopreventative data in specific patient populations.

Related Experiment Videos

Main Results:

  • Combination therapy with phototherapy shows enhanced activity at lower acitretin doses.
  • Anecdotal evidence suggests potential benefits of sequential/rotational use with biologics.
  • Acitretin has demonstrated chemopreventative effects against squamous cell cancers in high-risk patients.

Conclusions:

  • Acitretin is a versatile agent for psoriasis, effective in various therapeutic combinations.
  • Further clinical trials are essential to validate the efficacy and safety of acitretin with biologic agents.
  • Acitretin shows significant promise in preventing specific cancers in susceptible individuals.